HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- ((3- (trifluoromethyl)phenyl)methyl)- 2H- 1,4- benzothiazin- 3(4H)- one

a K(Ca)3.1 channel blocker; structure in first source

Also Known As:

NS6180

Networked: 5 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazines: 3
    - 4-((3-(trifluoromethyl)phenyl)methyl)-2H-1,4-benzothiazin-3(4H)-one: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiazines: 3
    - 4-((3-(trifluoromethyl)phenyl)methyl)-2H-1,4-benzothiazin-3(4H)-one: 5

Experts

1.	Wulff, Heike: 2 articles (01/2018 - 01/2013)
2.	Brown, Brandon M: 1 article (01/2018)
3.	Pressley, Brandon: 1 article (01/2018)
4.	Ando, Y: 1 article (01/2013)
5.	Beeton, Christine: 1 article (01/2013)
6.	Brown, D T: 1 article (01/2013)
7.	Chen, Y-J: 1 article (01/2013)
8.	Chiu, P: 1 article (01/2013)
9.	Christophersen, P: 1 article (01/2013)
10.	Coleman, N: 1 article (01/2013)

Related Diseases

1.	Colitis 01/01/2013 - "NS6180 represents a novel class of K(Ca) 3.1 channel inhibitors which inhibited experimental colitis, suggesting K(Ca) 3.1 channels as targets for pharmacological control of intestinal inflammation." 01/01/2022 - "Furthermore, we asses in vivo the effect of blocking KCa3.1 with ENV59-GP3 peptide or KCa3.1-blocker NS6180 on protection against DSS-induced acute colitis. " 01/01/2022 - "ENV59-GP3 peptide treatment showed reduction of the disease score in the DSS-induced acute colitis mice model, which was comparable to effects of the KCa3.1 channel blocker NS6180. " 01/01/2013 - "We characterized the benzothiazinone NS6180 (4-[[3-(trifluoromethyl)phenyl]methyl]-2H-1,4-benzothiazin-3(4H)-one) with respect to potency and molecular site of action on K(Ca) 3.1 channels, selectivity towards other targets, effects on T-cell activation as well as pharmacokinetics and inflammation control in colitis induced by 2,4-dinitrobenzene sulfonic acid, a rat model of inflammatory bowel disease (IBD). "
2.	Inflammation (Inflammations) 01/01/2013 - "NS6180 represents a novel class of K(Ca) 3.1 channel inhibitors which inhibited experimental colitis, suggesting K(Ca) 3.1 channels as targets for pharmacological control of intestinal inflammation." 01/01/2013 - "NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease." 01/01/2013 - "Despite poor plasma exposure, NS6180 (3 and 10 mg·kg(-1) b.i.d.) dampened colon inflammation and improved body weight gain as effectively as the standard IBD drug sulfasalazine (300 mg·kg(-1) q.d.). " 01/01/2013 - "We characterized the benzothiazinone NS6180 (4-[[3-(trifluoromethyl)phenyl]methyl]-2H-1,4-benzothiazin-3(4H)-one) with respect to potency and molecular site of action on K(Ca) 3.1 channels, selectivity towards other targets, effects on T-cell activation as well as pharmacokinetics and inflammation control in colitis induced by 2,4-dinitrobenzene sulfonic acid, a rat model of inflammatory bowel disease (IBD). "
3.	Body Weight (Weight, Body) 01/01/2013 - "Despite poor plasma exposure, NS6180 (3 and 10 mg·kg(-1) b.i.d.) dampened colon inflammation and improved body weight gain as effectively as the standard IBD drug sulfasalazine (300 mg·kg(-1) q.d.). "
4.	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/01/2023 - "In this study, we tested the effect of the selective blocker of KCa3.1 channel NS6180 on SOCE and the killing efficiency of NK cells from healthy donors and NK-92 cells against T-ALL cell line Jurkat. "
5.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/01/2013 - "NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease." 01/01/2013 - "We characterized the benzothiazinone NS6180 (4-[[3-(trifluoromethyl)phenyl]methyl]-2H-1,4-benzothiazin-3(4H)-one) with respect to potency and molecular site of action on K(Ca) 3.1 channels, selectivity towards other targets, effects on T-cell activation as well as pharmacokinetics and inflammation control in colitis induced by 2,4-dinitrobenzene sulfonic acid, a rat model of inflammatory bowel disease (IBD). "

Related Drugs and Biologics

1.	Sulfasalazine (Azulfidine)
2.	Peptides (Polypeptides)
3.	TRAM 34
4.	Sulfonic Acids
5.	Mitogens
6.	2,4-dinitrobenzene
7.	senicapoc